Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP907 | DOI: 10.1530/endoabs.41.EP907

ECE2016 Eposter Presentations Pituitary - Clinical (83 abstracts)

Serum N-terminal pro brain natriuretic peptide level in patients with prolactinoma who were treated with caborgoline

Mustafa Rasid Tasdelen 1 , Senay Arikan Durmaz 2 , Nesligül Yildirim 3 & Eyup Koc 4

1Kirikkale University Faculty of Medicine, Department of Internal Medicine, kirikkale, Turkey; 2Kirikkale University Faculty of Medicine, Department of Endocrinology, Kirikkale, Turkey; 3Kirikkale University Faculty of Medicine, Department of Cardiology, Kirikkale, Turkey; 4Kirikkale University Faculty of Medicine, Department of Nephrology, Kirikkale, Turkey.

Introduction and aim: Cabergoline, a long-lasting dopamine-agonist, is generally considered to be the safety drug for the treatment of prolactinoma. But, use of long time and high dose cabergoline may be a cause of cardiac valvulopathy in patient with prolactinoma. In present study, we aim to determine serum N-terminal probrain natriuretic peptide levels in patients with prolactinoma who were treated with cabergoline.

Materials and methods: Thirty patients with prolactinoma who applied to our endocrinology outpatient clinic (mean age 33.4±8.5 years and body mass index (BMI): 28.1±7.8 kg/m2), 30 age- and BMI matched (mean age 30.0±9.8 years; BMI: 26.8±6.4 kg/m2) patients who were determined another cause of hyperprolactinemia except prolactinoma, and age- and BMI matched healthy individuals (mean age 31.0±7.0 years; BMI: 25.2±2.9 kg/m2 were included in the study. Cumulative cabergoline dose was calculated in patients with prolactinoma who have received prior cabergoline therapy. Anthropometric measurements were performed. Blood pressure was measured in accordance with its thecnic. Serum samples for NT-pro BNP levels were stored −20° C. All biochemical and hormonal analysis were performed by automatic analyzer.

Results: We found that serum NT-pro BNP levels were not significantly different between study groups (63.9±39.8 pg/ml in prolactinoma group, 47.3±31.2 pg/ml in hyperprolactinemia group and 57.2±28.3 pg/ml in control group, P=0.160). Mean cumulative cabergoline dose (CCD) were calculated as 218.1±252.5 (range 52–1248 mg). However, we did not determine any correlations between serum NT-pro BNP levels and cumulative cabergoline dose, and between serum NT-pro BNP and prolactine levels. There was only a positive correlation between CCD and systolic blood tension (r=0.213, P=0.044).

Conclusions: According to our findings, cabergoline treatment does not influence serum NT-pro BNP levels in prolactinoma patients. Advanced studies which were included more patients with prolactinoma need to clarified this topic.

Keywords: Prolactinoma, cabergoline, NT-proBNP.

Article tools

My recent searches

No recent searches.